Report cover image

Global Ertapenem Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Oct 20, 2025
Length 194 Pages
SKU # APRC20556632

Description

Summary

According to APO Research, the global Ertapenem market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Ertapenem is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % from 2025 through 2031.

The Asia-Pacific market for Ertapenem is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Ertapenem market is expected to rise from $ million to $ million by 2031, at a CAGR of I% from 2025 through 2031.

The Europe market for Ertapenem is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Ertapenem market include Chongqing Fuan Pharmaceutical, Xiamen Amoipharm, Taiwan Savior Lifetec Corporation, Taiwan Grene Biotechnology, Kopran (Parijat Enterprises), Conderco and Canagen Pharmaceuticals Inc, etc. In 2024, the top three vendors accounted for approximately % of the market revenue.

This report presents an overview of global market for Ertapenem, revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Ertapenem, also provides the value of main regions and countries. Of the upcoming market potential for Ertapenem, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Ertapenem revenue, market share and industry ranking of main companies, data from 2020 to 2025. Identification of the major stakeholders in the global Ertapenem market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global Ertapenem company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.
Ertapenem Segment by Company

Chongqing Fuan Pharmaceutical
Xiamen Amoipharm
Taiwan Savior Lifetec Corporation
Taiwan Grene Biotechnology
Kopran (Parijat Enterprises)
Conderco
Canagen Pharmaceuticals Inc
Ertapenem Segment by Type

Purity:≤99%
Purity:Above 99%
Ertapenem Segment by Application

Injection Product
Table Product
Others
Ertapenem Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global Ertapenem status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Ertapenem key companies, revenue, market share, and recent developments.
3. To split the Ertapenem breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Ertapenem market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Ertapenem significant trends, drivers, influence factors in global and regions.
6. To analyze Ertapenem competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Ertapenem market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Ertapenem and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Ertapenem.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Ertapenem industry.
Chapter 3: Detailed analysis of Ertapenem company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Ertapenem in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Ertapenem in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

194 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Ertapenem Market Size, 2020 VS 2024 VS 2031
1.3 Global Ertapenem Market Size (2020-2031)
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Ertapenem Market Dynamics
2.1 Ertapenem Industry Trends
2.2 Ertapenem Industry Drivers
2.3 Ertapenem Industry Opportunities and Challenges
2.4 Ertapenem Industry Restraints
3 Ertapenem Market by Company
3.1 Global Ertapenem Company Revenue Ranking in 2024
3.2 Global Ertapenem Revenue by Company (2020-2025)
3.3 Global Ertapenem Company Ranking (2023-2025)
3.4 Global Ertapenem Company Manufacturing Base and Headquarters
3.5 Global Ertapenem Company Product Type and Application
3.6 Global Ertapenem Company Establishment Date
3.7 Market Competitive Analysis
3.7.1 Global Ertapenem Market Concentration Ratio (CR5 and HHI)
3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.7.3 2024 Ertapenem Tier 1, Tier 2, and Tier 3 Companies
3.8 Mergers and Acquisitions Expansion
4 Ertapenem Market by Type
4.1 Ertapenem Type Introduction
4.1.1 Purity:≤99%
4.1.2 Purity:Above 99%
4.2 Global Ertapenem Sales Value by Type
4.2.1 Global Ertapenem Sales Value by Type (2020 VS 2024 VS 2031)
4.2.2 Global Ertapenem Sales Value by Type (2020-2031)
4.2.3 Global Ertapenem Sales Value Share by Type (2020-2031)
5 Ertapenem Market by Application
5.1 Ertapenem Application Introduction
5.1.1 Injection Product
5.1.2 Table Product
5.1.3 Others
5.2 Global Ertapenem Sales Value by Application
5.2.1 Global Ertapenem Sales Value by Application (2020 VS 2024 VS 2031)
5.2.2 Global Ertapenem Sales Value by Application (2020-2031)
5.2.3 Global Ertapenem Sales Value Share by Application (2020-2031)
6 Ertapenem Regional Value Analysis
6.1 Global Ertapenem Sales Value by Region: 2020 VS 2024 VS 2031
6.2 Global Ertapenem Sales Value by Region (2020-2031)
6.2.1 Global Ertapenem Sales Value by Region: 2020-2025
6.2.2 Global Ertapenem Sales Value by Region (2026-2031)
6.3 North America
6.3.1 North America Ertapenem Sales Value (2020-2031)
6.3.2 North America Ertapenem Sales Value Share by Country, 2024 VS 2031
6.4 Europe
6.4.1 Europe Ertapenem Sales Value (2020-2031)
6.4.2 Europe Ertapenem Sales Value Share by Country, 2024 VS 2031
6.5 Asia-Pacific
6.5.1 Asia-Pacific Ertapenem Sales Value (2020-2031)
6.5.2 Asia-Pacific Ertapenem Sales Value Share by Country, 2024 VS 2031
6.6 South America
6.6.1 South America Ertapenem Sales Value (2020-2031)
6.6.2 South America Ertapenem Sales Value Share by Country, 2024 VS 2031
6.7 Middle East & Africa
6.7.1 Middle East & Africa Ertapenem Sales Value (2020-2031)
6.7.2 Middle East & Africa Ertapenem Sales Value Share by Country, 2024 VS 2031
7 Ertapenem Country-level Value Analysis
7.1 Global Ertapenem Sales Value by Country: 2020 VS 2024 VS 2031
7.2 Global Ertapenem Sales Value by Country (2020-2031)
7.2.1 Global Ertapenem Sales Value by Country (2020-2025)
7.2.2 Global Ertapenem Sales Value by Country (2026-2031)
7.3 USA
7.3.1 USA Ertapenem Sales Value Growth Rate (2020-2031)
7.3.2 USA Ertapenem Sales Value Share by Type, 2024 VS 2031
7.3.3 USA Ertapenem Sales Value Share by Application, 2024 VS 2031
7.4 Canada
7.4.1 Canada Ertapenem Sales Value Growth Rate (2020-2031)
7.4.2 Canada Ertapenem Sales Value Share by Type, 2024 VS 2031
7.4.3 Canada Ertapenem Sales Value Share by Application, 2024 VS 2031
7.5 Mexico
7.5.1 Mexico Ertapenem Sales Value Growth Rate (2020-2031)
7.5.2 Mexico Ertapenem Sales Value Share by Type, 2024 VS 2031
7.5.3 Mexico Ertapenem Sales Value Share by Application, 2024 VS 2031
7.6 Germany
7.6.1 Germany Ertapenem Sales Value Growth Rate (2020-2031)
7.6.2 Germany Ertapenem Sales Value Share by Type, 2024 VS 2031
7.6.3 Germany Ertapenem Sales Value Share by Application, 2024 VS 2031
7.7 France
7.7.1 France Ertapenem Sales Value Growth Rate (2020-2031)
7.7.2 France Ertapenem Sales Value Share by Type, 2024 VS 2031
7.7.3 France Ertapenem Sales Value Share by Application, 2024 VS 2031
7.8 U.K.
7.8.1 U.K. Ertapenem Sales Value Growth Rate (2020-2031)
7.8.2 U.K. Ertapenem Sales Value Share by Type, 2024 VS 2031
7.8.3 U.K. Ertapenem Sales Value Share by Application, 2024 VS 2031
7.9 Italy
7.9.1 Italy Ertapenem Sales Value Growth Rate (2020-2031)
7.9.2 Italy Ertapenem Sales Value Share by Type, 2024 VS 2031
7.9.3 Italy Ertapenem Sales Value Share by Application, 2024 VS 2031
7.10 Spain
7.10.1 Spain Ertapenem Sales Value Growth Rate (2020-2031)
7.10.2 Spain Ertapenem Sales Value Share by Type, 2024 VS 2031
7.10.3 Spain Ertapenem Sales Value Share by Application, 2024 VS 2031
7.11 Russia
7.11.1 Russia Ertapenem Sales Value Growth Rate (2020-2031)
7.11.2 Russia Ertapenem Sales Value Share by Type, 2024 VS 2031
7.11.3 Russia Ertapenem Sales Value Share by Application, 2024 VS 2031
7.12 Netherlands
7.12.1 Netherlands Ertapenem Sales Value Growth Rate (2020-2031)
7.12.2 Netherlands Ertapenem Sales Value Share by Type, 2024 VS 2031
7.12.3 Netherlands Ertapenem Sales Value Share by Application, 2024 VS 2031
7.13 Nordic Countries
7.13.1 Nordic Countries Ertapenem Sales Value Growth Rate (2020-2031)
7.13.2 Nordic Countries Ertapenem Sales Value Share by Type, 2024 VS 2031
7.13.3 Nordic Countries Ertapenem Sales Value Share by Application, 2024 VS 2031
7.14 China
7.14.1 China Ertapenem Sales Value Growth Rate (2020-2031)
7.14.2 China Ertapenem Sales Value Share by Type, 2024 VS 2031
7.14.3 China Ertapenem Sales Value Share by Application, 2024 VS 2031
7.15 Japan
7.15.1 Japan Ertapenem Sales Value Growth Rate (2020-2031)
7.15.2 Japan Ertapenem Sales Value Share by Type, 2024 VS 2031
7.15.3 Japan Ertapenem Sales Value Share by Application, 2024 VS 2031
7.16 South Korea
7.16.1 South Korea Ertapenem Sales Value Growth Rate (2020-2031)
7.16.2 South Korea Ertapenem Sales Value Share by Type, 2024 VS 2031
7.16.3 South Korea Ertapenem Sales Value Share by Application, 2024 VS 2031
7.17 India
7.17.1 India Ertapenem Sales Value Growth Rate (2020-2031)
7.17.2 India Ertapenem Sales Value Share by Type, 2024 VS 2031
7.17.3 India Ertapenem Sales Value Share by Application, 2024 VS 2031
7.18 Australia
7.18.1 Australia Ertapenem Sales Value Growth Rate (2020-2031)
7.18.2 Australia Ertapenem Sales Value Share by Type, 2024 VS 2031
7.18.3 Australia Ertapenem Sales Value Share by Application, 2024 VS 2031
7.19 Southeast Asia
7.19.1 Southeast Asia Ertapenem Sales Value Growth Rate (2020-2031)
7.19.2 Southeast Asia Ertapenem Sales Value Share by Type, 2024 VS 2031
7.19.3 Southeast Asia Ertapenem Sales Value Share by Application, 2024 VS 2031
7.20 Brazil
7.20.1 Brazil Ertapenem Sales Value Growth Rate (2020-2031)
7.20.2 Brazil Ertapenem Sales Value Share by Type, 2024 VS 2031
7.20.3 Brazil Ertapenem Sales Value Share by Application, 2024 VS 2031
7.21 Argentina
7.21.1 Argentina Ertapenem Sales Value Growth Rate (2020-2031)
7.21.2 Argentina Ertapenem Sales Value Share by Type, 2024 VS 2031
7.21.3 Argentina Ertapenem Sales Value Share by Application, 2024 VS 2031
7.22 Chile
7.22.1 Chile Ertapenem Sales Value Growth Rate (2020-2031)
7.22.2 Chile Ertapenem Sales Value Share by Type, 2024 VS 2031
7.22.3 Chile Ertapenem Sales Value Share by Application, 2024 VS 2031
7.23 Colombia
7.23.1 Colombia Ertapenem Sales Value Growth Rate (2020-2031)
7.23.2 Colombia Ertapenem Sales Value Share by Type, 2024 VS 2031
7.23.3 Colombia Ertapenem Sales Value Share by Application, 2024 VS 2031
7.24 Peru
7.24.1 Peru Ertapenem Sales Value Growth Rate (2020-2031)
7.24.2 Peru Ertapenem Sales Value Share by Type, 2024 VS 2031
7.24.3 Peru Ertapenem Sales Value Share by Application, 2024 VS 2031
7.25 Saudi Arabia
7.25.1 Saudi Arabia Ertapenem Sales Value Growth Rate (2020-2031)
7.25.2 Saudi Arabia Ertapenem Sales Value Share by Type, 2024 VS 2031
7.25.3 Saudi Arabia Ertapenem Sales Value Share by Application, 2024 VS 2031
7.26 Israel
7.26.1 Israel Ertapenem Sales Value Growth Rate (2020-2031)
7.26.2 Israel Ertapenem Sales Value Share by Type, 2024 VS 2031
7.26.3 Israel Ertapenem Sales Value Share by Application, 2024 VS 2031
7.27 UAE
7.27.1 UAE Ertapenem Sales Value Growth Rate (2020-2031)
7.27.2 UAE Ertapenem Sales Value Share by Type, 2024 VS 2031
7.27.3 UAE Ertapenem Sales Value Share by Application, 2024 VS 2031
7.28 Turkey
7.28.1 Turkey Ertapenem Sales Value Growth Rate (2020-2031)
7.28.2 Turkey Ertapenem Sales Value Share by Type, 2024 VS 2031
7.28.3 Turkey Ertapenem Sales Value Share by Application, 2024 VS 2031
7.29 Iran
7.29.1 Iran Ertapenem Sales Value Growth Rate (2020-2031)
7.29.2 Iran Ertapenem Sales Value Share by Type, 2024 VS 2031
7.29.3 Iran Ertapenem Sales Value Share by Application, 2024 VS 2031
7.30 Egypt
7.30.1 Egypt Ertapenem Sales Value Growth Rate (2020-2031)
7.30.2 Egypt Ertapenem Sales Value Share by Type, 2024 VS 2031
7.30.3 Egypt Ertapenem Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 Chongqing Fuan Pharmaceutical
8.1.1 Chongqing Fuan Pharmaceutical Comapny Information
8.1.2 Chongqing Fuan Pharmaceutical Business Overview
8.1.3 Chongqing Fuan Pharmaceutical Ertapenem Revenue and Gross Margin (2020-2025)
8.1.4 Chongqing Fuan Pharmaceutical Ertapenem Product Portfolio
8.1.5 Chongqing Fuan Pharmaceutical Recent Developments
8.2 Xiamen Amoipharm
8.2.1 Xiamen Amoipharm Comapny Information
8.2.2 Xiamen Amoipharm Business Overview
8.2.3 Xiamen Amoipharm Ertapenem Revenue and Gross Margin (2020-2025)
8.2.4 Xiamen Amoipharm Ertapenem Product Portfolio
8.2.5 Xiamen Amoipharm Recent Developments
8.3 Taiwan Savior Lifetec Corporation
8.3.1 Taiwan Savior Lifetec Corporation Comapny Information
8.3.2 Taiwan Savior Lifetec Corporation Business Overview
8.3.3 Taiwan Savior Lifetec Corporation Ertapenem Revenue and Gross Margin (2020-2025)
8.3.4 Taiwan Savior Lifetec Corporation Ertapenem Product Portfolio
8.3.5 Taiwan Savior Lifetec Corporation Recent Developments
8.4 Taiwan Grene Biotechnology
8.4.1 Taiwan Grene Biotechnology Comapny Information
8.4.2 Taiwan Grene Biotechnology Business Overview
8.4.3 Taiwan Grene Biotechnology Ertapenem Revenue and Gross Margin (2020-2025)
8.4.4 Taiwan Grene Biotechnology Ertapenem Product Portfolio
8.4.5 Taiwan Grene Biotechnology Recent Developments
8.5 Kopran (Parijat Enterprises)
8.5.1 Kopran (Parijat Enterprises) Comapny Information
8.5.2 Kopran (Parijat Enterprises) Business Overview
8.5.3 Kopran (Parijat Enterprises) Ertapenem Revenue and Gross Margin (2020-2025)
8.5.4 Kopran (Parijat Enterprises) Ertapenem Product Portfolio
8.5.5 Kopran (Parijat Enterprises) Recent Developments
8.6 Conderco
8.6.1 Conderco Comapny Information
8.6.2 Conderco Business Overview
8.6.3 Conderco Ertapenem Revenue and Gross Margin (2020-2025)
8.6.4 Conderco Ertapenem Product Portfolio
8.6.5 Conderco Recent Developments
8.7 Canagen Pharmaceuticals Inc
8.7.1 Canagen Pharmaceuticals Inc Comapny Information
8.7.2 Canagen Pharmaceuticals Inc Business Overview
8.7.3 Canagen Pharmaceuticals Inc Ertapenem Revenue and Gross Margin (2020-2025)
8.7.4 Canagen Pharmaceuticals Inc Ertapenem Product Portfolio
8.7.5 Canagen Pharmaceuticals Inc Recent Developments
9 Concluding Insights
10 Appendix
10.1 Reasons for Doing This Study
10.2 Research Methodology
10.3 Research Process
10.4 Authors List of This Report
10.5 Data Source
10.5.1 Secondary Sources
10.5.2 Primary Sources
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.